Contineum Therapeutics (CTNM) stock fell sharply after Bristol Myers Squibb (BMY) reported mixed Phase 3 trial results for its competing lung disease drug, admilparant. While one dose showed significant efficacy, another failed to reach statistical significance, raising concerns about the drug's dose-response profile and creating uncertainty for the broader LPAR1 antagonist class, including CTNM's lead asset, PIPE-791.
Contineum Therapeutics (CTNM) stock experienced a significant decline following the release of mixed Phase 3 trial results for Bristol Myers Squibb's (BMY) admilparant, a competing drug in the idiopathic pulmonary fibrosis (IPF) space. While BMY's 60mg dose showed significant efficacy, the 120mg dose did not achieve statistical significance, raising questions about the drug's dose-response. This outcome creates uncertainty for CTNM, whose lead asset, PIPE-791, is also an LPAR1 antagonist in Phase 2 trials for IPF. The market is interpreting BMY's mixed results as a potential de-risking for the LPAR1 antagonist class in terms of safety, but also as a cautionary tale regarding efficacy and dose-response, directly impacting investor confidence in CTNM's similar drug. This is a short-term negative for CTNM, as its future performance will now be more closely scrutinized against BMY's ongoing developments and the broader LPAR1 antagonist landscape.